



A**B**

Supplemental Figure 6. Early or late RDV treatment did not impact COVID-19 disease progression. RDV-treated patients were stratified based on their RDV treatment timing relative to days post-illness onset (PIO) (≤ 7 days ($n=12$, median 6 days PIO) or >7 days ($n=15$, median 9 days PIO)). Immune mediator levels in plasma samples collected before and one week after RDV treatment were measured and compared. Immune mediators were grouped based on their associations with **(A)** inflammatory or **(B)** T cell responses. Statistical analyses were performed with Kruskal Wallis test with Dunn's multiple comparison ($*P < 0.05$). Immune mediator levels for healthy controls ($n=23$) are indicated by the black dotted line. Patient samples with concentration out of measurement range are presented as the value of Limit of Quantification (LOQ).